DT-061, also known as DT061 or Dizoxin, is an investigational drug being developed for the treatment of Parkinson's disease. It is a dopamine agonist that works by binding to dopamine receptors in the brain and stimulating their activity. The chemical name for DT-061 is (±)-4-(1H-Imidazol-4-yl)-1-methyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid hydrochloride, and its molecular formula is C11H13N3O2 • HCl. Its molecular weight is 253.7 g/mol, and the CAS number for this compound is 1809427-19-7.
Top Ten Keywords and Synonyms
Health Benefits of DT-061 DT-061 has shown promising results in preclinical studies as a potential treatment for Parkinson's disease. It may offer improved efficacy compared to currently available treatments, as well as neuroprotective effects to slow down the progression of the disease. Its once-daily oral dosing regimen may also offer convenience to patients.
Potential Effects of DT-061 DT-061 is a dopamine agonist that works by stimulating dopamine receptors in the brain. This can potentially improve motor function in patients with Parkinson's disease and reduce the frequency and severity of motor fluctuations and dyskinesias associated with current levodopa-based therapies. In addition, DT-061 has been shown to have neuroprotective effects, potentially slowing down the progression of Parkinson's disease.
Product Mechanism DT-061 is a dopamine agonist that binds to dopamine receptors in the brain and stimulates their activity. By mimicking the effects of dopamine, it can potentially improve motor function in patients with Parkinson's disease. In addition, DT-061 has been shown to activate other monoamine neurotransmitter systems in the brain, which may contribute to its neuroprotective effects.
Safety DT-061 is still undergoing clinical trials, and its safety profile has not yet been fully established. However, preclinical studies and early-stage clinical trials suggest that it may be well-tolerated and safe for use in patients with Parkinson's disease. Ongoing clinical trials will continue to evaluate the safety and efficacy of DT-061.
Side Effects The potential side effects of DT-061 are not yet fully known, as it is still undergoing clinical trials. However, common side effects of dopamine agonists include nausea, vomiting, dizziness, and hallucinations. Patients should seek medical attention if they experience any symptoms of these conditions.
Dosing Information The optimal dosage of DT-061 for the treatment of Parkinson's disease is still being determined through ongoing clinical trials. Patients should follow their healthcare professional's instructions for dosing and administration.
Conclusion In conclusion, DT-061 is an investigational drug being developed for the treatment of Parkinson's disease. It is a dopamine agonist that works by stimulating dopamine receptors in the brain and may offer improved efficacy and neuroprotective effects compared to current treatments. Although its safety profile has not yet been fully established, early indications suggest that it may be well-tolerated and safe for use in patients with Parkinson's disease. Its development highlights the ongoing efforts to develop more effective and convenient treatments for patients with this debilitating disease.
